Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Scientists crack the code on scalable CAR-T cell production. Researchers at Boston Medical Center and Boston University have developed a method to reliably grow CD4+ helper T cells from stem cells — a key hurdle in making off-the-shelf CAR-T therapies a reality. The advance could one day mean cancer patients receive ready-made immune cell treatments without the costly, time-consuming process of personalized cell manufacturing.
Scientists crack the code on scalable CAR-T cell production
A team at Boston Medical Center and Boston University has cleared a major roadblock in cancer immunotherapy: reliably producing CD4+ helper T cells from induced pluripotent stem cells (iPSCs) at scale. Published in Stem Cell Reports, the findings bring the dream of "off-the-shelf" CAR-T therapies — pre-made immune cell treatments ready for any patient — significantly closer to reality.
The secret? Timing. The researchers found that manipulating the Notch signaling pathway — critical in early T cell development — was the key. By switching it off during later stages of cell maturation while also dialing down anti-T cell receptor signaling, they coaxed developing cells into becoming functional CD4+ T cells that closely resemble those found in human blood.
Key Takeaways
Why it matters: Current CAR-T therapies are personalized, expensive, and slow to produce. A scalable, off-the-shelf alternative could dramatically expand access to life-saving cancer treatment.
